NRTUA treatment altered IL-12, IFN-γ, and the CXCR3-stimulating cytokine-involved CD8+ T-cell population in the tumor microenvironment (TME), subsequently inhibiting melanoma tumor growth in mice116. Here, CD8A is linked to melanoma.